Danijela Gnjidic1, George O Agogo2, Christine M Ramsey2,3, Daniela C Moga4,5,6, Heather Allore2,7. 1. Faculty of Pharmacy and Charles Perkins Centre, University of Sydney, New South Wales, Australia. 2. Department of Internal Medicine, New Haven, Connecticut. 3. Yale Center for Medical Informatics, Yale School of Medicine, New Haven, Connecticut. 4. Department of Pharmacy Practice and Science, College of Pharmacy, Lexington. 5. Department of Epidemiology, College of Public Health, Lexington. 6. Sanders-Brown Center on Aging, University of Kentucky, Lexington. 7. Department of Biostatistics, Yale School of Public Health, New Haven, Connecticut.
Abstract
Background: Use of potentially inappropriate medications (PIM) among people with dementia is common. We assessed the patterns of medication use from 1-year before dementia diagnosis, to 1-year after dementia diagnosis, compared with patterns of medication use in people without dementia. Methods: We conducted longitudinal study using the National Alzheimer's Coordinating Center data. Adults aged 65 years and older newly diagnosed with dementia (n = 2,418) during 2005-2015 were year, age, and sex matched 1:1 with controls. Generalized estimating equation models weighted for missingness and adjusted for 15 participant characteristics were fit. Results: Among participants with dementia, number of medications reported 1-year prediagnosis was 8% lower than at diagnosis year (p < .0001) and 11% higher 1-year postdiagnosis compared with year of diagnosis (p < .0001). Among participants with dementia, the odds of PIM exposure, assessed using the 2015 Beers Criteria, was 17% lower 1-year prediagnosis (p < .0001) and 17% higher 1-year postdiagnosis (p = .006) compared with year of diagnosis. Among controls, there were approximately 6% more medications reported between consecutive years (p < .0001 each comparison) and the odds of PIM exposure increased 11% between consecutive years (p = .006 and p = .047). At each annual follow-up, participants with dementia had lower odds of PIM exposure than their controls (prediagnosis p < .0001, at diagnosis p = .0007, postdiagnosis p = .03, respectively). There were no differences in exposure to anticholinergic medications. Conclusions: Number of medications and PIM use increased annually for participants with and without dementia. Persistent challenge of increasing PIM use in this group of older adults is of major concern and warrants interventions to minimize such prescribing.
Background: Use of potentially inappropriate medications (PIM) among people with dementia is common. We assessed the patterns of medication use from 1-year before dementia diagnosis, to 1-year after dementia diagnosis, compared with patterns of medication use in people without dementia. Methods: We conducted longitudinal study using the National Alzheimer's Coordinating Center data. Adults aged 65 years and older newly diagnosed with dementia (n = 2,418) during 2005-2015 were year, age, and sex matched 1:1 with controls. Generalized estimating equation models weighted for missingness and adjusted for 15 participant characteristics were fit. Results: Among participants with dementia, number of medications reported 1-year prediagnosis was 8% lower than at diagnosis year (p < .0001) and 11% higher 1-year postdiagnosis compared with year of diagnosis (p < .0001). Among participants with dementia, the odds of PIM exposure, assessed using the 2015 Beers Criteria, was 17% lower 1-year prediagnosis (p < .0001) and 17% higher 1-year postdiagnosis (p = .006) compared with year of diagnosis. Among controls, there were approximately 6% more medications reported between consecutive years (p < .0001 each comparison) and the odds of PIM exposure increased 11% between consecutive years (p = .006 and p = .047). At each annual follow-up, participants with dementia had lower odds of PIM exposure than their controls (prediagnosis p < .0001, at diagnosis p = .0007, postdiagnosis p = .03, respectively). There were no differences in exposure to anticholinergic medications. Conclusions: Number of medications and PIM use increased annually for participants with and without dementia. Persistent challenge of increasing PIM use in this group of older adults is of major concern and warrants interventions to minimize such prescribing.
Authors: S S Mirra; A Heyman; D McKeel; S M Sumi; B J Crain; L M Brownlee; F S Vogel; J P Hughes; G van Belle; L Berg Journal: Neurology Date: 1991-04 Impact factor: 9.910
Authors: Duane L Beekly; Erin M Ramos; Gerald van Belle; Woodrow Deitrich; Amber D Clark; Mary E Jacka; Walter A Kukull Journal: Alzheimer Dis Assoc Disord Date: 2004 Oct-Dec Impact factor: 2.703
Authors: Mitchell R Redston; Sarah N Hilmer; Andrew J McLachlan; Alexander J Clough; Danijela Gnjidic Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472
Authors: George O Agogo; Christine M Ramsey; Danijela Gnjidic; Daniela C Moga; Heather Allore Journal: Int Psychogeriatr Date: 2018-04-18 Impact factor: 3.878
Authors: Jennifer Tjia; Becky A Briesacher; Daniel Peterson; Qin Liu; Susan E Andrade; Susan L Mitchell Journal: JAMA Intern Med Date: 2014-11 Impact factor: 21.873
Authors: Anna Renom-Guiteras; Petra A Thürmann; Ramón Miralles; Renate Klaaßen-Mielke; Ulrich Thiem; Astrid Stephan; Michel H C Bleijlevens; David Jolley; Helena Leino-Kilpi; Ingalill Rahm Hallberg; Kai Saks; Maria Soto-Martin; Adelaida Zabalegui; Gabriele Meyer Journal: Age Ageing Date: 2018-01-01 Impact factor: 10.668
Authors: Danijela Gnjidic; Sarah N Hilmer; Sirpa Hartikainen; Anna-Maija Tolppanen; Heidi Taipale; Marjaana Koponen; J Simon Bell Journal: PLoS One Date: 2014-01-13 Impact factor: 3.240
Authors: Danielle S Abraham; Thanh Phuong Pham Nguyen; Sean Hennessy; Daniel Weintraub; Shelly L Gray; Dawei Xie; Allison W Willis Journal: Age Ageing Date: 2020-08-24 Impact factor: 10.668
Authors: Sujita W Narayan; Sallie-Anne Pearson; Melisa Litchfield; David G Le Couteur; Nicholas Buckley; Andrew J McLachlan; Helga Zoega Journal: Br J Clin Pharmacol Date: 2019-07-07 Impact factor: 4.335
Authors: T Möllers; L Perna; H Stocker; P Ihle; I Schubert; B Schöttker; L Frölich; J Bauer; H Brenner Journal: Epidemiol Psychiatr Sci Date: 2019-11-14 Impact factor: 6.892
Authors: L P Dantas; A R C C Forte; B C Lima; C N S Sousa; E C Vasconcelos; P H C Lessa; R F Vieira; M C A Patrocínio; S M M Vasconcelos Journal: Braz J Med Biol Res Date: 2022-01-25 Impact factor: 2.590